irinotecan + oxaliplatin + raltitrexed

This is a combination chemotherapy regimen consisting of three small-molecule cytotoxic agents—irinotecan, oxaliplatin, and raltitrexed—used primarily in the treatment of advanced or metastatic colorectal cancer. - **Irinotecan** is a topoisomerase I inhibitor that prevents DNA unwinding and replication, leading to cell death. - **Oxaliplatin** is a platinum-based agent that forms DNA crosslinks, inhibiting DNA synthesis and function. - **Raltitrexed** is a thymidylate synthase inhibitor that disrupts DNA synthesis by blocking the formation of thymidine nucleotides. The combination aims to maximize antitumor efficacy by targeting different mechanisms involved in cancer cell proliferation and survival. This regimen has been studied as an option for patients with advanced colorectal cancer, particularly when standard fluoropyrimidine-based therapies (such as 5-fluorouracil) are unsuitable or have failed[1][2][3]. Clinical studies suggest this triple-drug approach may offer improved clinical effectiveness compared to single-agent or doublet regimens but can be associated with increased toxicity.

Other names

irinotecan + oxaliplatin + raltitrexed